ArticleJournal of inflammation research2025
Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect.
Lei Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.